FDA Suspends License for Chikungunya Vaccine

The regulatory agency said it ‘believes this vaccine is not safe and that continued administration to the public would pose a danger to health.’

A laboratory technician holds a mosquito at the World Mosquito Program factory in Medellin, Colombia, on June 4, 2024. Jaime Saldarriaga/AFP via Getty Images

Federal regulators on Aug. 25 said they’ve suspended approval for a vaccine against chikungunya, a mosquito-borne virus.

Due to reports of serious adverse events following administration of the vaccine, the Food and Drug Administration’s Center for Biologics Evaluation and Research (CBER) “believes this vaccine is not safe and that continued administration to the public would pose a danger to health,” the FDA said in a statement.